Journal
British Journal of Cancer
Publication Date
2017
Volume
116
Issue
10
Inclusive Pages
1247-1253
Document Type
Open Access Publication
DOI
10.1038/bjc.2017.67
Rights and Permissions
Uwe Pelzer, et al. 2017. Quality-adjusted survival with combination nal-IRI þ 5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysisBritish Journal of Cancer, 116(10): 1247–1253. DOI: 10.1038/bjc.2017.67 https://www.nature.com/articles/bjc201767 Copyright 2017 Cancer Research UK From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ 09 May 2017 This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Recommended Citation
Pelzer, Uwe; Blanc, Jean-Frédéric; Melisi, Davide; Cubillo, Antonio; Von Hoff, Daniel D.; Wang-Gillam, Andrea; Chen, Li-Tzong; Siveke, Jens T.; Wan, Yin; Solem, Caitlyn T.; Botteman, Marc F.; Yang, Yoojung; de Jong, Floris A.; and Hubner, Richard A., "Quality-adjusted survival with combination nal-IRI þ 5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: A Q-TWiST analysis." British Journal of Cancer. 116, 10. 1247-1253. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/5937
Figure_2_116_10_2017.jpg (50 kB)
Figure_3_116_10_2017.jpg (70 kB)
Table_1_116_10_2017.html (25 kB)
Table_2_116_10_2017.html (25 kB)
Table_3_116_10_2017.html (25 kB)
